Phase II Single-Arm Exploratory Study of Glutamine Combined with XELOX Regimen (Oxaliplatin plus Capecitabine), Bevacizumab and Sintilimab as First-Line Therapy for Advanced Colorectal Cancer with KRAS G12D Mutation